Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Chubb
Julphar
Covington
Citi
US Army
Mallinckrodt
Boehringer Ingelheim
Farmers Insurance
Fuji

Generated: October 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,703,181

« Back to Dashboard

Which drugs does patent 8,703,181 protect, and when does it expire?


Patent 8,703,181 protects ONIVYDE and is included in one NDA.

This patent has thirty-three patent family members in fifteen countries.

Summary for Patent: 8,703,181

Title:Liposomes useful for drug delivery
Abstract: The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provides methods of making the liposome compositions provided by the present invention.
Inventor(s): Hong; Keelung (San Francisco, CA), Drummond; Daryl C. (Pacifica, CA), Kirpotin; Dmitri (San Francisco, CA)
Assignee: Merrimack Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/654,373
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Delivery; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ipsen Inc
ONIVYDE
irinotecan hydrochloride
INJECTABLE, LIPOSOMAL;IV (INFUSION)207793-001Oct 22, 2015RXYesYes► Subscribe► Subscribe TREATMENT OF PANCREATIC CANCER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,703,181

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,147,867Liposomes useful for drug delivery► Subscribe
9,730,891Liposomes useful for drug delivery► Subscribe
9,717,723Liposomes useful for drug delivery► Subscribe
8,658,203Liposomes useful for drug delivery to the brain► Subscribe
9,724,303Liposomes useful for drug delivery► Subscribe
9,737,528Liposomes useful for drug delivery to the brain► Subscribe
8,329,213Liposomes useful for drug delivery► Subscribe
8,992,970Liposomes useful for drug delivery► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,703,181

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2005240131► Subscribe
Canada2566007► Subscribe
Canada2821167► Subscribe
Canada2928387► Subscribe
China103948545► Subscribe
China1980637► Subscribe
Denmark1746976► Subscribe
European Patent Office1746976► Subscribe300885Netherlands► Subscribe
European Patent Office1746976► Subscribe122017000042Germany► Subscribe
European Patent Office1746976► SubscribeCA 2017 00030Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Army
US Department of Justice
Cipla
Fuji
Novartis
Chinese Patent Office
UBS
Baxter
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot